Conference abstract · 2015
Conference abstractPublished 2014
A novel anti-diabetes drug development program
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Over the last 50 years, the most extensively used blood glucose controlling agents have been insulin and sulfonylurea derivatives. However, more recently developed anti-diabetes drugs exhibit moderate to serious side effects. Rosiglitazone and pioglitazone are the only anti-diabetes drugs that improve insulin resistance, the primary cause of type 2 diabetes. Nevertheless, they have severe side effects: liver damage. We have demonstrated that Cyclo (his-pro) plus zinc (Cyclo-Z) is very effective in lowering blood glucose levels and improving oral glucose tolerance in streptozocin-induced diabetic rats, genetic type 2 diabetic Goto-Kakizaki (G-K) rats, and genetically obese diabetic ob/ob mice. Furthermore, Cyclo-Z treatment reduced body weight in obese Sprague-Dawley rats and aged G-K rats by reducing food and water intake. In these studies and along with subsequent nine-month toxicological studies in rats, we have not observed any adverse effects of Cyclo-Z. In an FDA-IND approved Phase 1 clinical trial, acute (24 hr study) high doses of Cyclo-Z also did not demonstrate any adverse effects in human volunteers. Findings from a three month Phase 2a clinical trial showed significant reductions in body weight and HbA1c in mildly diabetic, obese patients without a single report of any side effects. A second Phase 2a clinical trial is currently underway with severely diabetic, obese subjects. Given that Cyclo-Z does not show any apparent untoward effects and yet it improves insulin resistance in both animals and humans, Cyclo-Z may potentially be the most significant FDA approved new drug for the treatment of both diabetes and obesity.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 10 Apr 2018
Development of new anti-diabetic drug from medicinal plant-genomic research
Research article · 2017
Candida for Developing Anti-Diabetics Drugs!
Conference abstract · 14 Sep 2015
Novel hybrid compounds from thiosemicarbazone and triazole as anti-diabetic agents and their antioxidant potentials
Opinion · 23 Jul 2023
Tailoring Diabetes Treatment: Personalized Approaches with Anti-Diabetic Drugs
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Community diabetes prevention: Effective, global impact
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Moon K Song”
